| CIR Circadian Receives $3M R&D Tax Incentive |
| 02/12/15 | PRICE SENSITIVE | 45.4KB | Share |
|
| CIR Circadian Board Changes and Renewal |
| 30/11/15 | PRICE SENSITIVE | 258.54KB | Share |
|
| CIR Trading Halt |
| 30/11/15 | PRICE SENSITIVE | 257.45KB | Share |
|
| CIR Circadian to regain VEGFR-3 intellectual property license |
| 23/10/15 | PRICE SENSITIVE | 47.36KB | Share |
|
| CIR Appendix 4E and Annual Financial Report 2015 |
| 19/08/15 | PRICE SENSITIVE | 935.84KB | Share |
|
| CIR Circadian Commences Wet AMD OPT-302 Clinical Trial |
| 01/07/15 | PRICE SENSITIVE | 256.43KB | Share |
|
| CIR Circadian receives IND approval from FDA for Wet AMD Phase 1 |
| 15/06/15 | PRICE SENSITIVE | 257.43KB | Share |
|
| CIR Circadian partner Eli Lilly presents IMC-3C5 Ph1 at ASCO |
| 02/06/15 | PRICE SENSITIVE | 829.98KB | Share |
|
| CIR Half Year Report and Accounts |
| 26/02/15 | PRICE SENSITIVE | 571.22KB | Share |
|
| CIR US Patent Granted for Soluble VEGFR-3 Traps |
| 28/01/15 | PRICE SENSITIVE | 179.31KB | Share |
|
| CIR Circadian Receives $2.2M R&D Tax Incentive |
| 23/01/15 | PRICE SENSITIVE | 38.07KB | Share |
|
| CIR Circadian Capital Raising Prospectus |
| 09/10/14 | PRICE SENSITIVE | 386.11KB | Share |
|
| CIR Circadian to Raise A$17.4 Million |
| 06/10/14 | PRICE SENSITIVE | 210.63KB | Share |
|
| CIR Trading Halt |
| 01/10/14 | PRICE SENSITIVE | 113.55KB | Share |
|
| CIR Circadian Allowed Key Patent for VEGFR-3 Traps in US |
| 23/09/14 | PRICE SENSITIVE | 177.09KB | Share |
|
| CIR Preliminary Final Report |
| 29/08/14 | PRICE SENSITIVE | 263.21KB | Share |
|
| CIR Opthea Awarded Grant for OPT-302 Manufacture |
| 23/06/14 | PRICE SENSITIVE | 125.98KB | Share |
|
| CIROpthea Completes Pre-IND Meeting with FDA |
| 12/05/14 | PRICE SENSITIVE | 130.88KB | Share |
|
| CIROPT-302 reduces established wet AMD lesions in the mouse |
| 06/05/14 | PRICE SENSITIVE | 678.8KB | Share |
|
| CIRCEO Terms of Employment |
| 23/04/14 | PRICE SENSITIVE | 202.72KB | Share |
|
| CIRHalf Year Report & Accounts |
| 21/02/14 | PRICE SENSITIVE | 1.06MB | Share |
|
| CIRCircadian Appoints CEO and Managing Director |
| 21/02/14 | PRICE SENSITIVE | 260.43KB | Share |
|
| CIROpthea Signs Cell Line Commercial License Agreement |
| 14/01/14 | PRICE SENSITIVE | 574.45KB | Share |
|
| CIRCircadian CEO and Board Changes |
| 03/12/13 | PRICE SENSITIVE | 21.25KB | Share |
|
| CIRPhase 1b oncology trial completed |
| 27/11/13 | PRICE SENSITIVE | 371.7KB | Share |
|
| CIRR&D Tax Incentive - Circadian To Receive Over $2.5m |
| 15/11/13 | PRICE SENSITIVE | 51.05KB | Share |
|
| CIROpthea Signs Manufacturing Agreement |
| 30/10/13 | PRICE SENSITIVE | 471.6KB | Share |
|
| CIRPhase 1a clinical oncology trial with VGX-100 update |
| 17/10/13 | PRICE SENSITIVE | 110.33KB | Share |
|
| CIROpen Briefing |
| 28/08/13 | PRICE SENSITIVE | 288.12KB | Share |
|
| CIRPreliminary Final Report |
| 27/08/13 | PRICE SENSITIVE | 648.19KB | Share |
|
| CIRFDA GRANTS HUMANITARIAN USE DEVICE DESIGNATION TO VEGF-D KIT |
| 02/07/13 | PRICE SENSITIVE | 113.7KB | Share |
|
| CIRUS patent granted covering use of VEGFR-3 |
| 17/06/13 | PRICE SENSITIVE | 81.39KB | Share |
|
| CIRVGX-100 Phase 1 oncology trial presented at ASCO 2013 |
| 04/06/13 | PRICE SENSITIVE | 1.51MB | Share |
|
| CIRVEGF-C shown to have major role in (AMD) |
| 09/05/13 | PRICE SENSITIVE | 780.59KB | Share |
|
| CIRVEGF-C shown to have major role in (AMD) |
| 09/05/13 | PRICE SENSITIVE | 168.95KB | Share |
|
| CIRCircadian grants world-wide licence to Santa Cruz |
| 08/03/13 | PRICE SENSITIVE | 77.42KB | Share |
|
| CIRCIRCADIAN COMMENCES WORDWIDE MARKETING AND SALES OF REAGENTS |
| 27/02/13 | PRICE SENSITIVE | 164.79KB | Share |
|
| CIRHalf Year Report & Accounts |
| 18/02/13 | PRICE SENSITIVE | 409.53KB | Share |
|
| CIRR&D Tax Incentive - Circadian Receives $1.3m |
| 07/02/13 | PRICE SENSITIVE | 26.94KB | Share |
|
| CIRVGX-100 Phase 1 Clinical Trial Program Update |
| 04/02/13 | PRICE SENSITIVE | 1.08MB | Share |
|
| CIRLicence Grant To Bio-Rad |
| 15/11/12 | PRICE SENSITIVE | 32.36KB | Share |
|
| CIRVGX-100 Poster Presentation at EORTC |
| 08/11/12 | PRICE SENSITIVE | 315.62KB | Share |
|
| CIRPreliminary Final Report |
| 23/08/12 | PRICE SENSITIVE | 1.31MB | Share |
|
| CIRCommercial launch of CUP Test |
| 27/06/12 | PRICE SENSITIVE | 46.09KB | Share |
|
| CIRPlacement |
| 12/06/12 | PRICE SENSITIVE | 37.49KB | Share |
|
| CIRReinstatement to Official Quotation |
| 12/06/12 | PRICE SENSITIVE | 30.35KB | Share |
|
| CIRSuspension From Official Quotation |
| 06/06/12 | PRICE SENSITIVE | 77.8KB | Share |
|
| CIRTrading Halt |
| 05/06/12 | PRICE SENSITIVE | 30.43KB | Share |
|
| CIRHealthscope publishes data on CUP Test |
| 09/03/12 | PRICE SENSITIVE | 273.54KB | Share |
|
| CIROpen Briefing - CEO on H1 Results and Outlook |
| 20/02/12 | PRICE SENSITIVE | 326.06KB | Share |
|
| CIRHalf Yearly Report and Accounts |
| 16/02/12 | PRICE SENSITIVE | 432.74KB | Share |
|
| CIRVGX-100 potential for improving corneal graft survival |
| 30/01/12 | PRICE SENSITIVE | 40.29KB | Share |
|
| CIRCircadian commences first Phase 1 clinical trial of VGX-100 |
| 09/01/12 | PRICE SENSITIVE | 32.42KB | Share |
|
| CIROpen Briefing - CEO on IND Status for VGX-100 |
| 15/11/11 | PRICE SENSITIVE | 332.69KB | Share |
|
| CIRFDA approves IND for VGX-100 |
| 31/10/11 | PRICE SENSITIVE | 183.66KB | Share |
|
| CIRClinical validation study of CUP Test commences |
| 10/10/11 | PRICE SENSITIVE | 50.18KB | Share |
|
| CIRCircadian files IND with FDA for VGX-100 |
| 30/09/11 | PRICE SENSITIVE | 45.83KB | Share |
|
| CIROpen Briefing - CEO on FY12 Outlook and VGX-100 Progress |
| 15/09/11 | PRICE SENSITIVE | 366.46KB | Share |
|
| CIRVGX-100 potential new therapy for Dry Eye Disease |
| 13/09/11 | PRICE SENSITIVE | 41.45KB | Share |
|
| CIRPreliminary Final Report |
| 23/08/11 | PRICE SENSITIVE | 1.19MB | Share |
|
| CIROpen Briefing - CEO on VGX-100 Clinical Development Plans |
| 14/07/11 | PRICE SENSITIVE | 313.09KB | Share |
|
| CIRCircadian launches level 1 ADR Program and OTCQX in US |
| 14/06/11 | PRICE SENSITIVE | 58.59KB | Share |
|
| CIRVEGF-C and VEGF-D Identified as Biomarkers |
| 07/06/11 | PRICE SENSITIVE | 542.49KB | Share |
|
| CIROpen Briefing - ImClone Phase 1 Trials |
| 07/04/11 | PRICE SENSITIVE | 343.51KB | Share |
|
| CIRCircadian's VGX-100 Inhibits Tumour Growth in Cancer Models |
| 06/04/11 | PRICE SENSITIVE | 1.37MB | Share |
|
| CIRCircadian's partner ImClone Systems commences first Phase 1 |
| 06/04/11 | PRICE SENSITIVE | 24.2KB | Share |
|
| CIRHalf Yearly Report and Accounts |
| 15/02/11 | PRICE SENSITIVE | 797.38KB | Share |
|
| CIRCIRCADIAN LAUNCHES FIRST DIAGNOSTIC FOR LAM LUNG DISEASE |
| 02/02/11 | PRICE SENSITIVE | 30.36KB | Share |
|
| CIRChugai Worldwide Licence |
| 13/01/11 | PRICE SENSITIVE | 39.89KB | Share |
|
| CIROpen Briefing - VEGF Patent and Ark Arbitration |
| 18/11/10 | PRICE SENSITIVE | 344.33KB | Share |
|
| CIRCIRCADIAN AND ARK SETTLE TRINAM ARBITRATION |
| 11/11/10 | PRICE SENSITIVE | 46KB | Share |
|
| CIRCircadian to be granted significant patents |
| 09/11/10 | PRICE SENSITIVE | 39.59KB | Share |
|
| CIROpen Briefing - LAM Diagnostic Partnership |
| 14/10/10 | PRICE SENSITIVE | 277.13KB | Share |
|
| CIRCircadian partners with Cincinnati Childrens Hospital |
| 30/09/10 | PRICE SENSITIVE | 52.33KB | Share |
|
| CIRCEO on FY11 Outlook and Strategic Focus |
| 09/09/10 | PRICE SENSITIVE | 394.05KB | Share |
|
| CIRVEGF-D Diagnostics Patent in USA Granted |
| 06/09/10 | PRICE SENSITIVE | 31.03KB | Share |
|
| CIRPreliminary Final Report |
| 20/08/10 | PRICE SENSITIVE | 1.3MB | Share |
|
| CIROpen Briefing. CEO on VGX-100 animal tumour model data |
| 04/05/10 | PRICE SENSITIVE | 392.59KB | Share |
|
| CIRVGX100 signif inhibits tumour growth in animal cancer models |
| 15/04/10 | PRICE SENSITIVE | 398.03KB | Share |
|
| CIRHalf Yearly Report and Accounts |
| 17/02/10 | PRICE SENSITIVE | 932.85KB | Share |
|
| CIRCircadian and CSIRO enter strategic research alliance |
| 07/12/09 | PRICE SENSITIVE | 27.56KB | Share |
|
| CIRCircadian subsidiary terminates licence to Ark Therapeutics |
| 29/10/09 | PRICE SENSITIVE | 38.24KB | Share |
|
| CIRManufacturing milestone achieved for cancer drug candidate |
| 13/10/09 | PRICE SENSITIVE | 34.21KB | Share |
|
| CIRCIR provides PerkinElmer rights to market research products |
| 07/09/09 | PRICE SENSITIVE | 24.99KB | Share |
|
| CIRCircadian granted key VEGF-C patent in Japan |
| 25/08/09 | PRICE SENSITIVE | 27.53KB | Share |
|
| CIRPreliminary Final Report |
| 20/08/09 | PRICE SENSITIVE | 1.32MB | Share |
|
| CIRCircadian granted key strategic VEGF-D patent in Europe |
| 18/06/09 | PRICE SENSITIVE | 35.03KB | Share |
|
| CIRLicensee Ark Therap. - Trinam Ph 3 Trial Enrols 1st Patient |
| 22/05/09 | PRICE SENSITIVE | 37.94KB | Share |
|
| CIROpen Briefing. CEO on Recent Achievements |
| 19/05/09 | PRICE SENSITIVE | 268.69KB | Share |
|
| CIRCIR partner ImClone presents positive VEGR-3 AB data at AACR |
| 22/04/09 | PRICE SENSITIVE | 3.61MB | Share |
|
| CIROpen Briefing on Cancer Diagnostic Commercialisation |
| 02/03/09 | PRICE SENSITIVE | 285.95KB | Share |
|
| CIR Circadian and Healthscope to commercialise cancer diagnostic |
| 25/02/09 | PRICE SENSITIVE | 34.4KB | Share |
|
| CIRHalf Yearly Report and Accounts |
| 13/02/09 | PRICE SENSITIVE | 1.06MB | Share |
|
| CIROpen Briefing - CEO on Trinam Phase III Trial |
| 22/01/09 | PRICE SENSITIVE | 261.88KB | Share |
|
| CIRUS FDA clearance received to commence Phase 3 Trinam trial |
| 09/01/09 | PRICE SENSITIVE | 185.13KB | Share |
|
